

TREATMENT AND PREVENTION OF PEDIATRIC MIGRAINE

Gage Rodriguez MD

Ochsner Pediatric Neurology

Ochsner Pediatric Headache

Gage.Rodriguez@ochsner.org

Ochsner Pediatric Update 2023





LEARNING OBJECTIVES

- Diagnose common presentations of pediatric headache
- Identify the red flag symptoms and signs in patients with secondary headache
- Discuss lifestyle modification and headache hygiene with patients and families
- Recognize which pediatric headache patients should be referred for imaging +/- specialist
- Develop a comprehensive headache action plan utilizing acute and preventive treatments

DISCLOSURES



No financial or relationship disclosures



discussing several therapies for the treatment of headache disorders in children. Even when these therapies have a labeled use for migraine in adults, the majority of them are unlabeled/investigational in children.



MIGRAINE PATHOPHYSIOLOGY

MIGRAINE PATHOPHYSIOLOGY

PEDIATRIC HEADACHE



Highly complex, inherited disorder of sensory processing




Recurrent headaches and associated symptoms with neurologic dysfunction also in interictal phase




TRIGEMINOVASCULAR

PEDIATRIC HEADACHE




TRIGEMINOVASCULAR

PEDIATRIC HEADACHE




5 phases of migraine



- Phases may overlap or vary

FMRI

PEDIATRIC HEADACHE



AURA

- Cortical spreading depolarization: bioelectrical phenomenon consisting of a wave of intense cortical neuronal activity associated with hyperemia followed by a more prolonged period of neuronal activity suppression associated with cortical oligemia
- Controversy: directly causes headache vs triggers rest of attack




Figure 2 Points of aura origin of all recorded attacks. Figure showing the complete visual field up to 26.5° eccentricity. The right visual field of the patient is from ($0-180^\circ$) and the left visual field is from ($180-360^\circ$). $n = 800$.


AURA

- May start in different areas within the same individual
 - May propagate silently in cortex without clinical manifestations
-
- Increased risks associated with aura:
 - Ischemic stroke
 - Patent foramen ovale
 - Parkinson's disease
 - Bipolar disorder
 - Panic disorder
 - Hypotheses: shared genetic factors, neuroexcitability, neurochemical function

HEADACHE

- Nociceptive activation of peripheral trigeminal nociceptors -> cortical spreading depression and sensitization of perivascular sensory nerve terminals
- OR abnormal central processing of normal sensory input from trigeminal system


PEDIATRIC HEADACHE



INTERICTAL

- Hypersensitive to light/sounds/odors, Cognitive dysfunction, dizziness, off-balance
- fMRI shows altered resting state functional connectivity: cortical regions, thalamus, hypothalamus, brainstem, amygdala, and cerebellum
- Reduced habituation prior to prodrome
- Bottom line: hyperresponsivity and lack of habituation


PEDIATRIC HEADACHE



CGRP

- Ubiquitous peptide found in brain, gut, vasculature, etc.
- Causes arterial vasodilation, neurogenic inflammation, activation of meningeal nociceptors
- Enhances synaptic transmission through glutamate transmission -> peripheral and central sensitization
- Bidirectional model between CGRP and CSD

PEDIATRIC HEADACHE



MOLECULAR MEDIATORS



**PITUITARY
ADENYLATE
CYCLASE-
ACTIVATING
POLYPEPTIDE
(PACAP):** ELEVATED
DURING ATTACKS



SEROTONIN:
TRIPTANS ARE
SEROTONIN (5-
HT)1B/1D RECEPTOR
AGONISTS



DOPAMINE:
MEDIATES YAWNING,
NAUSEA, DIFFICULTY
CONCENTRATING



OREXIN A/B:
MEDIATES DURAL
INPUT



NOREPINEPHRINE:
SLEEP WAKE
REGULATION AND
PAIN



OTHERS: INSULIN,
GLUCAGON, LEPTIN,
NEUROPEPTIDE Y,
SOMATOSTATIN,
CHOLECYSTOKININ,
ADH, MELATONIN

PREVALENCE



PEDIATRIC HEADACHE

60% of children/adolescents with significant headache


7-9% with migraine, more when including probable dx

Age 10: 5% boys and girls

Age 15: 5% boys and 7% girls

Age 20: 6% boys and 10% girls

$\frac{3}{4}$ managed by PCP, $\frac{1}{4}$ by neurology



PROGNOSIS

- Migraine is the leading cause of disability for children and adolescents worldwide
- $\frac{3}{4}$ of children will continue to have symptoms as adults
- **HOWEVER:**
 - $\frac{2}{3}$ of children respond to current therapies
 - Children who respond to preventive treatment have better headache control as adults

Table 4. Headache Severity at Initial Diagnosis and Follow-up*

Headache Severity	1983	1993	2003
No headache	0	15 (25)	16 (27)
Mild	20 (33)	16 (27)	9 (15)
Moderate or severe	40 (67)	29 (48)	35 (58)
Total	60 (100)	60 (100)	60 (100)

*Data are given as number (percentage) of patients.

HISTORY



PEDIATRIC HEADACHE

Include patient and parent

Consider allowing patient to draw migraine

Key components:


Monthly headache frequency (# of days in last 30 days counting both small and big headaches)

Pattern: intermittent/stable vs escalating

Location: point to pain

Pain quality: squeezing your head, knocking on head, head exploding, throbbing, stabbing, pressure

Pain scale: 1-10 or small-medium-big




POUNDING PAIN

VISUAL AURAS

NAUSEA

ASSOCIATED FEATURES



AURAS



VISUAL MOST COMMON:
SEEING EXTRA SPOTS, LINES,
OR LIGHTS, LOSS OF VISION.
NOT INCLUDING
ORTHOSTATIC CHANGES



SENSORY: NUMBNESS OR
TINGLING



WEAKNESS: ALL-OVER
MUSCLE FATIGUE VS
NUMBNESS LEADING TO
CLUMSINESS VS TRUE
PARESIS (FAMILIAL
HEMIPLEGIC MIGRAINE)




BRAINSTEM: VERTIGO,
DYSARTHRIA, DIPLOPIA,
TINNITUS, IMPAIRED
HEARING, LACK OF
COORDINATION, CONFUSION,
AND SOMETIMES LOSS OF
CONSCIOUSNESS

CRANIAL AUTONOMIC SYMPTOMS

- Eyes: Conjunctival injection, lacrimation, ptosis
 - Nose: nasal congestion or rhinorrhea
 - Face: facial flushing
 - Ears: ear pressure
-
- BILATERAL SYMPTOMS ARE COMMON IN MIGRAINE
 - Unilateral symptoms also possible with migraine but may suggest trigeminal autonomic cephalalgia

PEDIATRIC HEADACHE



HEADACHE RELATED DISABILITY: PEDMIDAS



PEDIATRIC HEADACHE

- tested and validated for ages 4 -18, covers last 3 months
 - mirrors the use of the adult MIDAS developed for adults age 20-50
- 1) How many days of school missed in last month 2/2 HA:
 - A) Full days
 - B) Half days
 - C) function <50% ability
 - 2) Days you could not do home activities (chores, homework) 2/2 HA
 - 3) Days you could not participate in activities (sports, going out) 2/2 HA
 - a) days you participated but at <50% of usual ability 2/2 HA

HEADACHE RELATED DISABILITY: PEDMIDAS



PedMIDAS Score Range	Disability Grade
0 to 10	Little to none
11 to 30	Mild
31 to 50	Moderate
Greater than 50	Severe

- Results scored on 50 point scale
- Can be followed over time to assess response to treatment

RELATED SYNDROMES

PEDIATRIC HEADACHE

Cyclical vomiting: episodes of recurrent emesis

Abdominal migraine: disabling abdominal pain w/wo HA

Benign paroxysmal torticollis: intermittent head tilt with malaise, pallor, irritability, ataxia, and nausea/vomiting

Benign paroxysmal vertigo: “drunk gait” or trouble standing up w/wo nystagmus

Colic: excessive crying as baby

Childhood periodic syndromes usually younger age

CV and AM persists in teens

COMORBIDITY



PEDIATRIC HEADACHE



Obesity: Higher BMI -> higher frequency/disability



Epilepsy: increased rate of migraine



Atopic: allergic rhinitis or conjunctivitis with increased migraine



Anxiety/depression: higher disability even when controlling for frequency




ADHD: associated with migraine, also causes stress, use of stimulants




Sleep: higher with narcolepsy and restless leg syndrome

INFLUENCES



PEDIATRIC HEADACHE



SOCIAL

Adverse childhood events (physical/emotional/sexual abuse, financial stress, parental divorce, recent death, mental illness, addiction) have been shown to predispose to headache in childhood and later

Consider HEADS exam for teenagers

PEDIATRIC HEADACHE

Table 3. Logistic Regression Models Examining the Association Between Number of ACEs and History of Frequent or Severe Headaches (Including Migraine) in Children Ages 3-17 Years

ACE Score for a Child	Unadjusted OR (95% CI)	Adjusted OR (95% CI) ^{†, †}
No ACE	Ref	Ref
1 ACE	1.65 (1.31, 2.07)	1.34 (1.07, 1.68)
2 ACE	2.74 (2.12, 3.54)	2.15 (1.66, 2.80)
3 ACE	2.93 (2.20, 3.90)	1.89 (1.40, 2.53)
4 or more ACE	5.26 (4.10, 6.75)	3.4 (2.61, 4.43)

† Adjusted OR: adjusted for age, sex, race, ethnicity, depression, anxiety, epilepsy, brain injury, average sleep, and weight concern.

PHYSICAL EXAM

PEDIATRIC HEADACHE

Rule out: Facial asymmetry, visual/eye abnormalities, papilledema, motor asymmetry

Vitals: hypertension, tachycardia, serial HCs

Neck: limitations or pain with motion


Sinuses: palpate for tenderness

Jaw: Assess for TMJ (pain, clicking)

Allodynia: rub forehead and scalp, palpate occipital nerves

Continuous/positional headache: orthostatic vitals





RED FLAGS

Headache is due to life threatening causes (e.g. brain tumor) in:

- 2-3% of children presenting to EC
- 1% of children in primary care setting



SNOOP4Y

PEDIATRIC HEADACHE

Red Flag	Significance
Systemic signs/symptoms	
Fever, acute symptoms	Infections ranging from minor to serious ³⁵ are the most common cause of headache in children in the emergency department
Head trauma	Relatively common cause for headache in the emergency department
Vomiting	Consistent with migraine ³⁸ but also a risk factor for brain tumors ³⁹
Weight loss	Can be a symptom of malignancy
Comorbidities	Many systemic illnesses, including rheumatologic, oncologic, vascular, and hematologic conditions; genetic syndromes; and abnormalities of the immune system predispose to other serious causes for headache
Medications	Headache can be a medication side effect ⁴⁰
Neurologic signs/symptoms	Abnormal gait, ataxia, papilledema, changes in personality/behavior/cognition, visual disturbances/eye movement abnormalities, and seizure ³⁹ are red flags for serious secondary headache

LP

SNOOP4Y

PEDIATRIC HEADACHE

Onset sudden	Thunderclap onset of headache in which pain peaks instantly is rare in children but can signal serious causes such as cerebral hemorrhage or reversible cerebral vasoconstriction syndrome; the full range of differential diagnosis from adults with thunderclap headache should be considered, and imaging should be pursued
Onset in sleep/early morning	Headache causing a child to awaken from sleep or occurring early in the morning has been associated with intracranial lesions ⁴¹ and can be suggestive of sleep apnea and other sleep disorders ⁴² ; however, this diurnal pattern is also common in primary headache disorders ⁴³
Positional exacerbation	
Worse upright	Headache that resolves when supine and worsens immediately upon standing or slowly throughout the day can suggest spontaneous intracranial hypotension or postural tachycardia syndrome ³³
Worse supine	Consider increased intracranial pressure from tumor or idiopathic intracranial hypertension

SNOOPPPPY

PEDIATRIC HEADACHE

Precipitated by Valsalva	Brief headaches triggered by Valsalva maneuvers can signal intracranial abnormalities; headache triggered by cough along with signs/symptoms of brainstem/cerebellum/cervical spinal cord dysfunction ³⁸ may suggest Chiari malformation (although Chiari malformation may be found incidentally with other headaches and is of varying significance)
Parents (lack of family history)	Several studies have found that lack of family history of headaches is associated with higher odds of having a serious cause of headache in children ³⁹ ; most children with migraine have a family history of migraine, although the parent(s)/guardian(s) may not be aware of the diagnosis
Progressive or new	Significant change in the headache pattern, new headache, or progressively escalating headache raises the level of concern for secondary cause ⁴⁴ ; however, many new-onset headaches are not caused by structural brain abnormalities ⁴⁴ and may be attributed to relatively benign causes such as viral infections; furthermore, studies have used different cutoff points from days to months ⁴⁵ when trying to determine when a “recent-onset” headache is worrisome, so the newness of the headache must be interpreted with the presence or absence of other headache features
Young age	Some studies have found that children of younger age (defined as either ≤ 5 years ^{45,46} or ≤ 7 years ³⁹) were more likely to be diagnosed with a life-threatening headache, whereas other studies have refuted that concern ⁴⁴



WHEN NOT TO IMAGE

- Stable frequency of headaches
- Absence of red flags
- Normal neuro exam

Unnecessary imaging -> increased costs

Recommendations

1. Obtaining a neuroimaging study on a routine basis is not indicated in children with recurrent headaches and a normal neurologic examination (Level B; class II and class III evidence).
2. Neuroimaging should be considered in children with an abnormal neurologic examination (e.g., focal findings, signs of increased intracranial pressure, significant alteration of consciousness), the coexistence of seizures, or both (Level B; class II and class III evidence).
3. Neuroimaging should be considered in children in whom there are historical features to suggest the recent onset of severe headache, change in the type of headache, or if there are associated features that suggest neurologic dysfunction (Level B; class II and class III evidence).

LABS



PEDIATRIC HEADACHE

No general recommendations, send based on clinical picture

Basic headache labs to consider:

CBC (anemia)

CMP (electrolyte imbalance, liver/kidney dysfunction)

Iron panel (iron deficiency with or without anemia)

TSH (hypo and hyper can lead to headache)

ESR/CRP (inflammation, confirm iron studies)

PRIMARY HEADACHE DISORDERS



Migraine: ~7-9%



Tension headache: ~10-24%



Trigeminal autonomic cephalgias:
RARE (cluster in teens <0.1%)



Primary stabbing headache: RARE

Table 3 Comparison between the headache population younger than 6 years of age and 100 consecutive school headache patients older than 6 years of age selected in 2003

Headache type	Headache children younger than 6 years	Headache children older than 6 years
Migraine, %	35.2	57.0
Episodic tension headache, %	18.1	17.0
Chronic daily headache, %	4.8	13.0
Idiopathic stabbing headache, %	12.4	3.0
Post-traumatic headache, %	17.1	8.0
Other secondary headaches, %	9.5	2.0

EPIODIC MIGRAINE

PEDIATRIC HEADACHE

In children and adolescents, migraine duration may last 2-72 hours

Migraine is more often bilateral

Migraine headache is often frontotemporal

Subset of patients have facial pain – still grouped under migraine

Episodic: 1-14 days per month

High frequency episodic: 8-14 days per month

Diagnostic criteria:

- A. At least five attacks¹ fulfilling criteria B-D
- B. Headache attacks lasting 4-72 hr (untreated or unsuccessfully treated)^{2,3}
- C. Headache has at least two of the following four characteristics:
 - 1. unilateral location
 - 2. pulsating quality
 - 3. moderate or severe pain intensity
 - 4. aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
- D. During headache at least one of the following:
 - 1. nausea and/or vomiting
 - 2. photophobia and phonophobia
- E. Not better accounted for by another ICHD-3 diagnosis.

MIGRAINE WITH AURA

PEDIATRIC HEADACHE

Visual aura is most common (90% of aura)

Common patient mistakes:

- incorrect lateralization
- sudden vs. gradual onset
- monocular (retinal migraine) instead of homonymous visual disturbances
- mistaking sensory disturbance for weakness
- aura duration

A. At least two attacks fulfilling criteria B and C

B. One or more of the following fully reversible aura symptoms:

1. visual
2. sensory
3. speech and/or language
4. motor
5. brainstem
6. retinal

C. At least three of the following six characteristics:

1. at least one aura symptom spreads gradually over ≥ 5 minutes
2. two or more aura symptoms occur in succession
3. each individual aura symptom lasts 5-60 minutes¹
4. at least one aura symptom is unilateral²
5. at least one aura symptom is positive³
6. the aura is accompanied, or followed within 60 minutes, by headache

D. Not better accounted for by another ICHD-3 diagnosis.

CHRONIC MIGRAINE

PEDIATRIC HEADACHE



Headache occurring on 15 or more days per month for greater than 3 months, with migrainous features on more than 8 days per month

- A. Headache (migraine-like or tension-type-like¹) on ≥ 15 days/month for > 3 months, and fulfilling criteria B and C
- B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 *Migraine without aura* and/or criteria B and C for 1.2 *Migraine with aura*
- C. On ≥ 8 days/month for > 3 months, fulfilling any of the following²:
 - 1. criteria C and D for 1.1 *Migraine without aura*
 - 2. criteria B and C for 1.2 *Migraine with aura*
 - 3. believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative
- D. Not better accounted for by another ICHD-3 diagnosis^{3;4;5}.

TENSION HEADACHE

PEDIATRIC HEADACHE


Mild-moderate, non-disabling head pain

Lack of associated symptoms such as nausea/vomiting

Occurs in 10-24% of children and adolescents

But may do not seek care due to mild attacks

Treat with NSAIDs/Tylenol



TRIGEMINAL AUTONOMIC CEPHALGIAS

Rare in children

Cluster headache

Paroxysmal hemicrania

Hemicrania continua

short-lasting unilateral neuralgiform headache attacks

unilateral headache +/- prominent cranial parasympathetic autonomic features, lateralized and ipsilateral to the headache.

Restlessness present, may be less pronounced in childhood

TRIGEMINAL AUTONOMIC CEPHALGIAS

PEDIATRIC HEADACHE

Syndrome	Pain location	Attack duration	Autonomic features	Migrainous features	Exacerbants
Trigeminal autonomic cephalalgias					
Cluster	Unilateral frontal/temporal/periorbital	Minutes to hours	Always	Sometimes	Alcohol, sleep
Paroxysmal hemicrania	Unilateral frontal/temporal/periorbital	Minutes	Always	Sometimes	Neck turning
Short-lasting unilateral neuralgiform headache attack syndromes (SUNHA)	Unilateral V1	Seconds to minutes	Always	Rarely	Cutaneous, thermal, mechanical
Hemicrania continua	Unilateral	Minutes or hours superimposed on baseline pain	Always	Often	Variable

PRIMARY STABBING HEADACHE


Very brief episodes of stabbing pain, can be severe

NO autonomic features

Usually only require treatment if frequent

Overlap with migraine

PEDIATRIC HEADACHE



FREQUENT/DAILY HAS



PEDIATRIC HEADACHE

1.5% of children: several times weekly or daily headaches

More common in female, increasing with age

Chronic migraine: ≥ 15 headache days, 8 or more migraine

High rates of disability in teens with chronic migraine



DAILY HEADACHES

PEDIATRIC HEADACHE

Physical/sexual abuse more common in these patients

Majority have anxiety related to school

Subset with significant psych disease / school phobia
(may contribute to seasonal pattern)

Acute family financial stress more common

Depression and anxiety -> worse disability

Poor sleep -> poor response to therapy

Table 3. MANOVA analysis of differences between adolescents with and without a lifetime psychiatric comorbidity.

	Psychiatric comorbidity (n = 42)	No psychiatric comorbidity (n = 51)		
	Mean (SD)	Mean (SD)	F	P
PedMIDAS Total Score	71.12 (35.05)	53.94 (27.23)	7.07	.009*
PedsQL Child/Teen Report	68.11 (16.13)	75.83 (12.36)	6.82	.010*
PedsQL Parent Report	69.95 (14.90)	77.02 (15.93)	4.80	.031*


*Statistically significant at .05. MANOVA: multivariate analysis of variance; PedMIDAS: Pediatric Migraine Disability Assessment; PedsQL: The Pediatric Quality of Life Inventory.

Variable	History of Abuse (n = 8)		No History of Abuse (n = 114)	
	Mean	SD	Mean	SD
Headache frequency (0–28)	24.57	6.02	20.78	5.47
Pain intensity (VAS)	6.10	0.72	5.56	1.69
CDI (0–54)	13.63	10.19	7.62	6.42
PedMIDAS total score (0–540)	62.63	29.59	65.25	35.56

NEW DAILY PERSISTENT HEADACHE

- No history of significant headache
 - Distinct onset, present ever since for 3+ months
 - May continue years or decades
 - 1/5 of all pediatric patients with 'chronic daily headache'
-
- MOST TREATMENT RESISTENT HEADACHE TYPE, REFER ASAP

PEDIATRIC HEADACHE



ACUTE ACTION PLAN

PEDIATRIC HEADACHE

- All patients with migraine should be given an acute treatment plan for headache
- school note to excuse at symptom onset so patient can hydrate, take acute med, and rest
- <https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.13681>

Green Zone – Prevent more headaches		
<p>Do or take this every day to help prevent YOUR headaches:</p> <p>It may take 4-6 weeks to see a big change, so stick with it! Visit www.headacherelease.com to manage your headaches</p>		<ul style="list-style-type: none"> • Get enough sleep; keep a regular schedule • Eat healthy foods; don't skip meals • Drink enough water; avoid caffeine • Get regular exercise; manage your weight • Learn ways to relax; manage your stress <p><i>Directions to provider:</i> Set 1-2 healthy lifestyle goals. Consider a daily med's or vitamin supplement if > 1 headache per week. Consider Cognitive Behavior Therapy (CBT) if PedIMIDAS > 10. To download PedIMIDAS, visit https://www.cincinnatichildrens.org/service/h/headache-center/pedmidas</p>
Yellow Zone – Don't wait. Act fast to treat your headaches		
<p>☐ Go to school nurse or health office right away. Take your quick-relief medicine as soon as your headache starts:</p> <p>Take _____ Dose _____ Route _____ May repeat after _____ hours.</p> <p>Take _____ Dose _____ Route _____ May repeat after _____ hours.</p> <p>Let your provider know if you need to take your quick relief medicines 3 or more days a week or if this plan isn't working.</p> <p>☐</p>		<ul style="list-style-type: none"> • Drink some water or sports drink if you can • Rest in a dark, quiet place for 30 minutes and practice your relaxation exercises (e.g., deep breathing, guided imagery), if you can • You may need a different PE activity, dark glasses, or a quiet place to work for a while <p><i>Directions to provider:</i> Goal is pain-free within 1-2 hours for intermittent headaches and back to baseline for constant headaches. Consider NSAID +/- antiemetic, a triptan or a combination of medications.</p>
		<p><i>Directions to provider:</i> Optional section for other scenarios, step 2 or a "backup" plan. Home "backup" plan: Consider dopamine blocker +/- diphenhydramine +/- NSAID.</p>
Red Zone – Time to get more help		
<p>Contact your provider's office if:</p> <ul style="list-style-type: none"> • Your headache is much worse, lasting much longer than usual <p>Go to the Emergency Room if:</p> <ul style="list-style-type: none"> • You have new and very different symptoms like loss of vision, unable to move one side of your face or body, trouble walking or talking, very confused or unable to respond 		<ul style="list-style-type: none"> • Call 9-1-1 if child loses consciousness or has stroke-like symptoms <p><i>Directions to provider:</i> Avoid giving aspirin to children < 16 years old. Avoid giving opioids or butalbital for pain.</p>
<p>I authorize the quick-relief medication(s) listed in the Yellow Zone:</p> <p>Provider's Signature _____ Date _____</p> <p>Parent/Guardian's Signature _____ Date _____</p>		
<p>☐ to be administered by school personnel ☐ to be self-administered by student ☐ to be administered only by parent</p>		

FIRST STEP



**Ibuprofen 7.5-10mg/kg/dose,
given every 4-6 hrs prn migraine**

Ibuprofen has nearly 3x odds of efficacy as placebo (OR 2.9, 95% CI 1.0-8.1), and 2x odds as acetaminophen (OR 2.2, 95% CI 1.1-4.0)



Alternative: naproxen 5-6mg/kg/dose given q8h prn migraine



Avoiding NSAIDs?: acetaminophen 15mg/kg/dose q4-6hrs



Avoiding all meds? devices


WHY NOT OPIOIDS?

Opioids should not be used routinely for migraine therapy!

Opioid use → pain receptor changes → less responsive to other migraine medication → escalation of opioid use → medication overuse headache

A national practice variation study has found that pediatric migraineurs leaving pediatric ER received opioids 5.4% of time but triptans only 1% of time

PEDIATRIC HEADACHE



MEDICATION OVERUSE

PEDIATRIC HEADACHE

NSAIDS	Simple analgesics (NSAIDs/Tylenol): limit to 14 days or less per month
TRIPTANS	Triptans: limit to 9 days or less per month
COMBO	Combo analgesics (with caffeine): limit to 9 days or less per month



DEVICES

External trigeminal nerve stimulator (Cefaly): no prescription, acute and preventive mode, available online, FDA approved 12+

Remote electrical neuromodulation (Nerivio): acute and preventive, online prescription needed, FDA approved 12+

PEDIATRIC HEADACHE



CEFALY

PEDIATRIC HEADACHE

External trigeminal nerve stimulator

Stimulates supraorbital/supratrochlear nerves, feels like pinching rubber band

Available OTC with money back trial period

Authorized for age 8+ for acute and preventive

PREMICE RCT: 38% responder rate vs 12% sham

Safe for use in children but tolerability may be issue



NERIVIO



Remote electrical neuromodulation device



Generates signal in arm pain fibers which induces pain modulation, causes mild tingling sensation



Study in teens: 71% with some response, 35% pain free at 2 hrs



Approved for 12+ for acute and prevention



Can fill out prescription online or fax form

PEDIATRIC HEADACHE



TRIPTANS

Should be considered if first line ineffective

Recommended triptans for adolescents (12+):

- Sumatriptan/naproxen tab
- Rizatriptan tab or ODT
- Almotriptan tab
- Nasal spray sumatriptan
- Nasal spray zolmitriptan

Younger children (6-11): rizatriptan 5mg tab or ODT

	Time to onset (hrs)	Half Life (hrs)	Preparations and Dosing
<i>Fast Active Triptans</i>			
Sumatriptan	1.5	2-2.5	Tab: 1mg/kg/dose, 25mg (<50kg), 50mg (>50kg), 100mg Nasal Spray: 5mg (<50kg, <9yrs), 10mg (>10-11 yrs), 20mg (>50kg, >12yrs)
Zolmitriptan*	2	2.5-3	Regular/ZMT: 2.5mg (<12yrs), 5mg (>12 yrs) Nasal Spray: 5mg (>12 yrs)
Rizatriptan*	1.2-2.5	2-3	Regular ODT: 5mg (<40kg), 10mg (>40kg)
Almotriptan*	1.4-3.8	3.2-3.7	Tab: 6.25mg or 12.5mg or 25mg (>50kg)
Eletriptan	1-2	4-7	Tab: 20mg or 40mg (>50kg)
<i>Slow Active Triptans</i>			
Naratriptan	2-3	5-6	Tab: 1mg, 2.5mg
Frovatriptan	2-4	24-30	Tab: 2.5mg

*FDA approved medication for children

TRIPTANS

PEDIATRIC HEADACHE

Triptans are serotonin 5HT_{1B,1D} receptor agonists – block release of vasoactive peptides at trigeminal nucleus caudalis

Most effective if taken when pain is still mild, which tends to be earlier in attack (does not shorten aura duration)


But... only 1/3 of patients pain free at 2 hours

And... 1/4 of migraineurs do not respond to triptans



TRIPTAN TRIALS

PEDIATRIC HEADACHE



TRIPTAN DATA

PEDIATRIC HEADACHE

Name	Dosing	FDA approval	# of pediatric trials
*almotriptan PO	6.25mg or 12.5mg	Yes, 12-17 year olds	1 (positive)
*rizatriptan MLT	5mg MLT 20-39kg 10mg MLT ≥ 40kg	Yes, 6-17 year olds	2 (both positive)
zolmitriptan PO	2.5mg, 5mg, or 10mg	No	2 → 1 high placebo response; 1 similar efficacy (at 2.5mg) as ibuprofen
*zolmitriptan NS	2.5mg or 5mg NS	Yes, 12-17 year olds	2 (all positive, 1 with placebo challenge)
sumatriptan NS	5mg, 10mg (if <40kg) or 20mg NS	No (AAN parameter only)	3 (all positive)
sumatriptan injectible	3mg (<30kg), 6kg (>30kg), or 0.06mg/kg	No	2 (1990's, open label)
sumatriptan PO	50mg or 100mg	No	1 (not more effective than placebo)
*sumatriptan/naproxen PO	Suma 10mg/ naproxen 60mg (can increase to 85mg/500mg)	Yes, 12-17 year olds	2 (both positive)
* FDA approved			



TRIPTAN CONTRAINDICATIONS

Avoid in patients with a history of cardiovascular disease, including stroke, transient ischemic attacks, myocardial infarction, severe peripheral vascular disease, ischemic bowel disease, and coronary vasospasm, including Prinzmetal angina

Avoid in patients with cardiac accessory conduction pathway disorders, including Wolff-Parkinson-White syndrome

Based on known pharmacology and effects on vascular muscle in triptans rather than absolute contraindications

less common in pediatric patients but should be considered

Per FDA, triptans are contraindicated in those with a history of hemiplegic aura or migraine with brainstem aura. This contraindication was based on a view of migraine pathophysiology that is no longer considered current.

TRIPTAN OPTIONS

PEDIATRIC HEADACHE

6-11yo: rizatriptan 5mg tab or ODT

Unable to swallow pills: rizatriptan ODT, sumatriptan NS, zolmitriptan NS

Rapid escalation or significant nausea: sumatriptan NS and zolmitriptan NS

Terrible insurance: sumatriptan tabs (\$6), rizatriptan (\$4)

Side effects -> use triptans with slower onset (naratriptan, frovatriptan)

Prices for popular triptans

Viewing 13 of 13 medications

Popularity ▾



Imitrex (sumatriptan)

as low as **\$14**

Sumatriptan (Imitrex) is an inexpensive drug used to treat migraines. It is more popular than comparable drugs. It is available in generic and brand versions. Generic **sumatriptan** is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower.

[See Prices](#)

[More Info](#)



Maxalt-Mlt (rizatriptan)

as low as **\$15**

Rizatriptan (Maxalt, Maxalt-mlt) is a moderately priced drug used to treat migraines with or without aura. An aura is a strange feeling or visual disturbance that warns you of an attack. It is not used to prevent migraines. It is slightly more popular than comparable drugs. It is available in multiple generic and brand versions. Generic **rizatriptan** is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower.


[See Prices](#)

[More Info](#)

SEROTONIN SYNDROME

PEDIATRIC HEADACHE

- In 2006, FDA warned about risk of serotonin syndrome in patients taking triptans concurrently with SSRI or SNRIs
- Triptans do not interact with the 5HT2 receptor
- Therefore not pharmacologically plausible that triptan use could precipitate serotonin syndrome in someone on an SSRI or SNRI
- American Headache Society position paper:
 - “With only Class IV evidence available in the literature and available through the FDA registration of adverse events, inadequate data are available to determine the risk of serotonin syndrome with the addition of a triptan to SSRIs/SNRIs or with triptan monotherapy.”



ANTI-NAUSEA MEDS

PEDIATRIC HEADACHE

Consider adding as third step if significant nausea/vomiting

Data limited in peds

Can consider DRAs which can help both nausea and migraine pain:

Prochlorperazine 5-10mg q8h prn, metoclopramide 5-10mg q8h prn

BUT must take with dose of Benadryl (12.5-25mg) to prevent extrapyramidal side effects

Ondansetron also an option but frequent use could worsen HA

SMART LIFESTYLE

PEDIATRIC HEADACHE

Factor	Advice
Sleep: consistent and sufficient	
Bedtime and wake-up time	Maintain a consistent bedtime routine and avoid daytime napping to prevent disruptions to the sleep-wake cycle ⁹⁹ ; children 3-5 years of age should sleep 10-13 hours per day (including naps), children 6-12 years of age should sleep 9-12 hours per day, and teenagers should sleep 8-10 hours per day ¹⁰⁰
Problems falling asleep	Use bed only for sleep, turn off screens at least 1-2 hours before bed to limit blue light exposure ¹⁰¹
Problems staying asleep	Consider causes such as sleep apnea, depression
Daytime somnolence	Consider causes such as sleep apnea, depression

SMART LIFESTYLE

PEDIATRIC HEADACHE

Meals and hydration: consistent and sufficient

Missed meals	Recognize that fasting can be a trigger
Well-balanced diet	Eat a variety of fruits and vegetables, protein, and dairy (or another source of vitamin D)
Access problems or limited time	Address time limitations and food insecurity with individualized solutions; consider social work consult
Water consumption	≥8 cups per day for children older than 9 years of age (more for teenage boys and extra at times of high exertion) ¹⁰²
Other beverage consumption	Limit to avoid weight gain as obesity is associated with worsened migraine frequency and disability ²¹
Caffeine consumption	High caffeine consumption is associated with increased odds of headache in adolescents, ⁹⁵ probably because of caffeine withdrawal ¹⁰³

Activity: consistent and sufficient

Address inactivity	Inactivity in adolescents is associated with higher odds of migraine ⁹⁵ ; weight loss in overweight teenagers can contribute to headache improvement ²¹
Exercise	Meta-analyses in adults have concluded that exercise may be a beneficial and safe treatment for migraine ¹⁰⁴

FOOD TRIGGERS

PEDIATRIC HEADACHE



Papetti review showed no evidence that chocolate, tyramine/phenylalanine containing foods, caffeine, alcohol, MSG, aspartame, or nitrites act as triggers for pediatric migraine



While some nutrients seem to play a role in inducing migraine attacks, it is necessary to verify the strict cause and effect relationship before making restrictive dietary changes



Focus more on a well-balance diet and not skipping meals rather than specific foods or elimination diets



SMART LIFESTYLE

PEDIATRIC HEADACHE

Relaxation: cope with stress and prevent migraines

Sources of stress	Home-related stressors (eg, arguments with siblings, observing parental disagreements) or school-related stressors (eg, difficulty in school, fear of doing poorly) can be triggers for headache
Help cope with stressors	Validate the normalcy and commonality of stressors and discuss coping strategies
Relaxation strategies	Cognitive-behavioral therapy can help migraine in children ¹⁰⁵ ; mindfulness-based stress reduction looks promising ¹⁰⁶

Triggers: avoidance/management

Weather	Changes in weather patterns are commonly reported as headache triggers; use of long-acting triptans may help to prevent migraine attacks around storms ¹⁰⁷
Specific foods	Little evidence shows that foods other than alcohol and caffeine are consistent headache triggers, although many patients report avoiding specific foods
Menses	Refer to the section on menstrual migraine

COGNITIVE BEHAVIORAL THERAPY


PEDIATRIC HEADACHE

Coping strategies for migraine disability, education on gate theory of pain, progressive muscle relaxation, diaphragmatic breathing, guided imagery, meditation, biofeedback

Peds meta-analysis: reduced headaches immediately and at 3mo follow-up

Teens with chronic migraine: CBT+amitriptyline superior to amitriptyline alone

Other studies have shown reduction in headaches **INDEPENDENT** of change in anxiety/depression symptoms



HEADACHE DIARY

PEDIATRIC HEADACHE



Total number of days with any headache



Number of headache days considered bad/severe



Focus on days not pain scale



Essential to track response to treatment



Many apps available or can print a blank calendar

- Most educational migraine tracker: [Migraine Buddy](#)
- Most comprehensive pain tracker: [Manage My Pain Pro](#)
- Most simple migraine tracker to use: [Headache Log](#)
- Best app for managing blue light exposure: [Blue Light Filter & Night Mode](#)
- Best to manage sleeplessness and anxiety: [BetterSleep Relax and Sleep](#)
- Best migraine tracker for sharing with your doctor: [Health Log](#)
- Most detailed record keeping: [N1 Headache](#)
- Best for community: [Bezzie Migraine](#)

PREVENTION



Consider with frequent headaches (4/month) or significant disability with attacks



Many prescription preventives have not shown efficacy over placebo in pediatric trials



Placebo response may be beneficial if no harm done, so at minimum should consider nutraceuticals with little/no s/e



May take 6-8 weeks to see improvement



Goal for improvement: headache frequency cut in half



Can stop after at least 6 months of headache stability

NUTRACEUTICALS



PEDIATRIC HEADACHE

- Preliminary data supports use of magnesium and Coq10 for pediatric prevention
- Safety shown with vitamin D and riboflavin, mixed data for efficacy
- Once daily dosing better for adherence
- Take these every single day regardless of headache
- Unable to swallow pills: gummies, chewable tabs, liquid drops

Nutraceuticals ¹¹⁴			
Riboflavin	50-400 mg/d either once daily or divided into two doses	Urine discoloration	Limited studies
Magnesium	Elemental magnesium 9 mg/kg/d with food (magnesium oxide divided 3 times a day; others used)	Diarrhea	Limited studies, some positive
Coenzyme Q10	1-3 mg/kg/d in the morning with food	Insomnia, gastrointestinal upset	Limited studies, some positive
Vitamin D	Studies have used 400 IU/d for children with normal blood level of Vitamin D; 800 IU/d for mild and 5000 IU/d for moderate Vitamin D deficiency	Well tolerated	Limited studies
Melatonin ¹¹⁵	2-3 mg every day at bedtime	Sedation	Limited studies, some positive

RIBOFLAVIN (VITAMIN B2)

PEDIATRIC HEADACHE



50-400mg per day in 1-2 doses



400mg in adults, effective dose in children may be lower



Yamanaka et al 2020: faster time to pain freedom in migraine and/or reduced migraine frequency in children as young as 6



Safe and well-tolerated, may darken urine or cause mild GI upset



MAGNESIUM



Dose up to 9mg/kg/day, max 400mg



Elemental magnesium or magnesium oxide



Well tolerated, may cause GI upset or diarrhea



Meta-analysis of IV mag shows efficacy as acute tx in adults



Lack of high quality evidence in peds

PEDIATRIC MIGRAINE



COENZYME Q10

1-3mg/kg/day in the morning with food

Well tolerated but may cause insomnia and/or GI upset

Limited studies in peds, some positive

MELATONIN

PEDIATRIC HEADACHE



2-3mg 30-60min prior to bedtime



May inhibit CGRP release and NO synthesis



0.3mg/kg shown to reduce migraine frequency, severity, and impact on life



Less effective than amitriptyline (62% vs 82% in recent RCT)



VITAMIN D

400IU daily if normal level

800IU/d for mild deficiency

5000IU/d for moderate deficiency

Lower levels in patients with migraine vs control

6mo of therapy -> reduces symptom severity and migraine related disability

PEDIATRIC HEADACHE



BARRIERS



5-40% adolescents with chronic headache had not seen any provider in past year



Delayed referral to specialist -> higher 10 yr risk of chronic migraine



Underdiagnosed:
~17% migraine, ~36% "headache", ~45% no headache diagnosis



Correct diagnosis of migraine leads to better treatment outcomes

BARRIERS

Of patients awaiting neurology referral from PCP:

5% of those who would qualify for preventive treatment received prevention

NONE received a triptan

17% seen within 4mo

In our study group, 46.6% (395/849) of children were referred to the neurology department for more than a year after the onset of migraine. About 19% of patients consulted with a neurologist between 6 and 12 months (161/849), 9.2% (78/849) were evaluated by a neurologist between 4 and 6 months, and only in 17.5% (149/849) of cases, it was a consultation obtained in less than 4 months. With 7.5% (63/849) of patients, it was unknown how long it took to access a child neurologist after the onset of migraine as the parents and children could not recall the onset of symptoms. The time to see a headache specialist was not separately analyzed.

BARRIERS

- General neurologists: 28.7% triptan usage, 63% nutraceuticals, 37% prescription prevention
- Headache specialists: 56.7% triptan usage, 38.7% nutraceuticals, 66% prescription prevention
- No statistically significant difference in treatment outcomes but different patient populations

Table 2.—Comparison of Management Practices Between Headache Specialist and Non-Headache Specialists N = 469

Treatment Variable	Headache Specialist (N = 135)	General Neurologist (N = 334)	<i>P</i> -Value	95% CI for the Difference in Proportion
Imaging	93 (68.9%)	248 (74.2%)	.238	(−15.0%, 4.3%)
Triptan use	76 (56.7%)	96 (28.7%)	<.001	(18.1%, 38.5%)
Use of natural supplement for prophylaxis	52 (38.7%)	212 (63.7%)	<.001	(−35.4%, −15%)
Use of prescription drugs for prophylaxis	90 (66.7%)	125 (37.4%)	<.001	(19.2%, 39.3%)
Short-term outcome of treatment				
No significant improvement	36 (26.7%)	74 (22.2%)	.483	(−4.7%, 13.7%)
Mild to moderate improvement	63 (46.7%)	150 (44.7%)		
Significant improvement	36 (26.3%)	108 (32.3%)		

SPECIFIC QUESTIONS





Can email me at Gage.Rodriguez@ochsner.org for more questions



If able to access E-consults for pediatric neurology at Ochsner can send E-consult and it will route to my inbox

Summary

- Migraine is underdiagnosed and undertreated in the pediatric population
- Patients should receive a headache diagnosis, treatment action plan, education on lifestyle goals, and prompt referral when indicated
- Action plans should utilize OTC meds and triptan if these are ineffective
- Consider prevention in patients with frequent ($>4/30$) or disabling headaches



©1991, Novartis Pharmaceuticals Corporation. All rights reserved.



references

- 1. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. *Dev Med Child Neurol* 2010;52(12):1088–1097. doi: 10.1111/j.1469-8749.2010.03793.x
- 2. Wober-Bingol C Epidemiology of migraine and headache in children and adolescents. *Curr Pain Headache Rep* 2013;17(6):341. doi: 10.1007/s11916-013-0341-z
- 3. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. *Headache* 1993;33(1):29–35. doi: 10.1111/j.1526-4610.1993.hed3301029.x
- 4. Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. *Neurology* 2012;79(18):1881–1888. doi: 10.1212/WNL.0b013e318271f812
- 5. Brna P, Dooley J, Gordon K, Dewan T. The prognosis of childhood headache: a 20-year follow-up. *Arch Pediatr Adolesc Med* 2005;159(12):1157–1160. doi: 10.1001/archpedi.159.12.1157
- 6. Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2019;93(11):487–499. doi: 10.1212/WNL.0000000000008095
- 7. Oskoui M, Pringsheim T, Billingshurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2019;93(11):500–509.
- 10. Stafstrom CE, Rostasy K, Minster A. The usefulness of children’s drawings in the diagnosis of headache. *Pediatrics* 2002;109(3):460–472. doi: 10.1542/peds.109.3.460
- 11. Cuvellier JC, Mars A, Vallee L. The prevalence of premonitory symptoms in paediatric migraine: a questionnaire study in 103 children and adolescents. *Cephalalgia* 2009;29(11):1197–1201. doi: 10.1111/j.1468-2982.2009.01854.x
- 12. Gelfand AA, Reider AC, Goadsby PJ. Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. *Neurology* 2013;81(5):431–436. doi: 10.1212/WNL.0b013e31829d872a [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 13. Mamouri O, Cuvellier JC, Duhamel A, et al. Postdrome symptoms in pediatric migraine: a questionnaire retrospective study by phone in 100 patients. *Cephalalgia* 2018;38(5):943–948. doi: 10.1177/0333102417721132
- 14. Hershey AD, Powers SW, Vockell ALB, et al. Development of a patient-based grading scale for PedMIDAS. *Cephalalgia* 2004;24(10):844–849. doi: 10.1111/j.1468-2982.2004.00757.x
- 15. Cincinnati Children’s. PedMIDAS tool for assessing migrain disability. Accessed April 10, 2023. cincinnatichildrens.org/service/h/headache-center/pedmidas
- 16. Hershey AD, Powers SW, Nelson TD, et al. Obesity in the pediatric headache population: a multicenter study. *Headache* 2009;49(2):170–177. doi: 10.1111/j.1526-4610.2008.01232.x
- 17. Oakley CB, Kossoff EH. Pediatric headache and seizures. *Semin Pediatr Neurol* 2017;24(4):310–319. doi: 10.1016/j.spen.2017.10.003
- 18. Wang IC, Tsai JD, Lin CL, et al. Allergic rhinitis and associated risk of migraine among children: a nationwide population-based cohort study. *Int Forum Allergy Rhino* 2016;6(3):322–327. doi: 10.1002/alar.21654
- 19. Özge A, Öksüz N, Ayta S, et al. Atopic disorders are more common in childhood migraine and correlated headache phenotype. *Pediatr Int* 2014;56(6):868–872. doi: 10.1111/ped.12381
- 20. Fuh JL, Wang SJ, Lu SR, et al. Headache disability among adolescents: a student population-based study. *Headache* 2010;50(2):210–218. doi: 10.1111/j.1526-4610.2009.01531.x
- 21. Salem H, Vivas D, Cao F, et al. ADHD is associated with migraine: a systematic review and meta-analysis. *Eur Child Adolesc Psychiatry* 2018;27(3):267–277. doi: 10.1007/s00787-017-1045-4
- 22. Gil-Gouveia R, Martins IP. Cognition and cognitive impairment in migraine. *Curr Pain Headache Rep* 2019;23(11):84. doi: 10.1007/s11916-019-0824-7
- 23. Mansuri F, Nash MC, Bakour C, Kip K. Adverse childhood experiences (ACEs) and headaches among children: a cross-sectional analysis. *Headache* 2020;60(4):735–744. doi: 10.1111/head.13773
- 24. Linder SL. Understanding the comprehensive pediatric headache examination. *Pediatr Ann* 2005;34(6):442–446. doi: 10.3928/0090-4481-20050601-08
- 25. Mack KJ, Johnson JN, Rowe PC. Orthostatic intolerance and the headache patient. *Semin Pediatr Neurol* 2010;17(2):109–116. doi: 10.1016/j.spen.2010.04.006

- 26. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia* 2018;38(1):1–211. doi: 10.1177/0333102417738202
- 27. Blume HK, Szperka CL. Secondary causes of headaches in children: when it isn't a migraine. *Pediatr Ann* 2010;39(7):431–439. doi: 10.3928/00904481-20100623-10
- 28. Ahmed MAS, Ramseyer-Bache E, Taylor K. Yield of brain imaging among neurologically normal children with headache on waking or headache waking the patient from sleep. *Eur J Paediatr Neurol* 2018;22(5):797–802. doi: 10.1016/j.ejpn.2018.06.001 [PubMed] [CrossRef] [Google Scholar]
- 29. Rho YI, Chung HJ, Suh ES, et al. The role of neuroimaging in children and adolescents with recurrent headaches—multicenter study. *Headache* 2011;51(3):403–408. doi: 10.1111/j.1526-4610.2011.01845.x [PubMed] [CrossRef] [Google Scholar]
- 30. Raieli V, Eliseo M, Pandolfi E, et al. Recurrent and chronic headaches in children below 6 years of age. *J Headache Pain* 2005;6(3):135–142. doi: 10.1007/s10194-005-0168-z [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 31. Trofimova A, Vey BL, Mullins ME, et al. Imaging of children with nontraumatic headaches. *AJR Am J Roentgenol* 2018;210(1):8–17. doi: 10.2214/AJR.17.18561
- 32. Victor TW, Hu X, Campbell JC, et al. Migraine prevalence by age and sex in the United States: a life-span study. *Cephalalgia* 2010;30(9):1065–1072. doi: 10.1177/0333102409355601
- 33. Raieli V, Pitino R, Giordano G, et al. Migraine in a pediatric population: a clinical study in children younger than 7 years of age. *Dev Med Child Neurol* 2015;57(6):585–588. doi: 10.1111/dmcn.12679
- 34. Eidlitz-Markus T, Zeharia A. Younger age of migraine onset in children than their parents: a retrospective cohort study. *J Child Neurol* 2018;33(1):92–97. doi: 10.1177/0883073817739197
- 35. Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. *Neurology* 2007;69(1):16–25. doi: 10.1212/01.wnl.0000265212.90735.64
- 36. Aegidius KL, Zwart JA, Hagen K, et al. Increased headache prevalence in female adolescents and adult women with early menarche. The Head-HUNT Studies. *Eur J Neurol* 2011;18(2):321–328. doi: 10.1111/j.1468-1331.2010.03143.x
- 37. Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. *Neurology* 2006;66(2):193–197. doi: 10.1212/01.wnl.0000183555.54305.fd
- 38. Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). *Headache* 2011;51(5):693–706. doi: 10.1111/j.1526-4610.2011.01885.x
- 39. Gladstein J, Holden EW. Chronic daily headache in children and adolescents: a 2-year prospective study. *Headache* 1996;36(6):349–351. doi: 10.1046/j.1526-4610.1996.3606349.x
- 40. Zafar M, Kashikar-Zuck SM, Slater SK, et al. Childhood abuse in pediatric patients with chronic daily headache. *Clin Pediatr (Phila)* 2012;51(6):590–593. doi: 10.1177/0009922811407181
- 41. Fujita M, Fujiwara J, Maki T, et al. Pediatric chronic daily headache associated with school phobia. *Pediatr Int* 2009;51(5):621–625. doi: 10.1111/j.1442-200X.2009.02804.x
- 42. Lu SR, Fuh JL, Wang SJ, et al. Incidence and risk factors of chronic daily headache in young adolescents: a school cohort study. *Pediatrics* 2013;132(1):e9–e16. doi: 10.1542/peds.2012-1909
- 43. Slater SK, Kashikar-Zuck SM, Allen JR, et al. Psychiatric comorbidity in pediatric chronic daily headache. *Cephalalgia* 2012;32(15):1116–1122. doi: 10.1177/0333102412460776
- 44. Probyn K, Bowers H, Caldwell F, et al. Prognostic factors for chronic headache: a systematic review. *Neurology* 2017;89(3):291–301. doi: 10.1212/WNL.0000000000004112
- 45. Turner SB, Rende EK, Pezzuto T, et al. Pediatric Migraine Action Plan (PedMAP). *Headache* 2019;59(10):1871–1873. doi: 10.1111/head.13681
- 46. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society Evidence assessment of migraine pharmacotherapies. *Headache* 2015;55(1):3–20. doi: 10.1111/head.12499
- 47. Sun H, Bastings E, Temeck J, et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. *JAMA Pediatr* 2013;167(3):243–249. doi: 10.1001/jamapediatrics.2013.872
- 48. Hershey AD, Lin T, Gruper Y, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. *Headache* 2020. doi: 10.1111/head.14042
- 49. Torres-Ferrus M, Vila-Sala C, Quintana M, et al. Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study). *Cephalalgia* 2019;39(1):91–99. doi: 10.1177/0333102418777509
- 50. Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended amount of sleep for pediatric populations: a consensus statement of the American Academy of Sleep Medicine. *J Clin Sleep Med* 2016;12(6):785–786. doi: 10.5664/jcsm.5866



- 51. Lemmens J, De Pauw J, Van Soom T, et al. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. *J Headache Pain* 2019;20(1):16. doi: 10.1186/s10194-019-0961-8
- 52. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. *Neurology* 2004;62(5):788–790. doi: 10.1212/01.wnl.0000113747.18760.d2
- 53. Orr SL. The evidence for the role of nutraceuticals in the management of pediatric migraine: a review. *Curr Pain Headache Rep* 2018;22(5):37. doi: 10.1007/s11916-018-0692-6
- 54. Gelfand AA, Goadsby PJ. The role of melatonin in the treatment of primary headache disorders. *Headache* 2016;56(8):1257–1266.
- 55. Kienbacher C, Wöber C, Zesch HE, et al. Clinical features, classification and prognosis of migraine and tension-type headache in children and adolescents: a long-term follow-up study. *Cephalalgia* 2006;26(7):820–830. doi: 10.1111/j.1468-2982.2006.01108.x
- 56. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. *Headache* 2013;53(1):81–92. doi: 10.1111/j.1526-4610.2012.02265.x
- 57. Lai LL, Koh L, Ho JA, et al. Off-label prescribing for children with migraines in U.S. ambulatory care Settings. *J Manag Care Spec Pharm* 2017;23(3):382–387. doi: 10.18553/jmcp.2017.23.3.382
- 58. Galinski M, Sidhoum S, Cimerman P, et al. Early diagnosis of migraine necessary in children: 10-year follow-up. *Pediatr Neurol* 2015;53(4):319–323. doi: 10.1016/j.pediatrneurol.2015.05.013
- 59. Seng EK, Gelfand AA, Nicholson RA. Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: a retrospective observational study of health systems data. *Cephalalgia* 2019;39(8):1000–1009. doi: 10.1177/0333102419833080
- 60. Gutta R, Valentini KJ, Kaur G, et al. Management of childhood migraine by headache specialist vs non-headache specialists. *Headache* 2019;59(9):1537–1546. doi: 10.1111/head.13660
- 61. de Tommaso M, Ambrosini A, Brighina F, et al. Altered processing of sensory stimuli in patients with migraine. *Nat Rev Neurol* 2014;10(3):144–155. doi:10.1038/nrneurol.2014.14 - DOI
- 62. Goadsby PJ, Holland PR. An update: pathophysiology of migraine. *Neurol Clin* 2019;37(4):651–671. doi:10.1016/j.ncl.2019.07.008 - DOI
- 63. Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. *Nat Rev Neurol* 2018;14(12):699–710. doi:10.1038/s41582-018-0098-4 - DOI
- 64. Hansen JM, Goadsby PJ, Charles AC. Variability of clinical features in attacks of migraine with aura. *Cephalalgia* 2016;36(3):216–224. doi:10.1177/0333102415584601 - DOI
- 65. Peng KP, May A. Redefining migraine phases—a suggestion based on clinical, physiological, and functional imaging evidence. *Cephalalgia* 2020;40(8):866–870. doi:10.1177/0333102419898868 - DOI
- 66. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. *Neurology* 2003;60(6):935–940. doi:10.1212/01.wnl.0000052998.58526.a9 - DOI
- 67. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. *Brain* 2014;137(pt 1):232–241. doi:10.1093/brain/awt320 - DOI
- 68. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. *Brain* 2016;139(pt 7):1987–1993. doi:10.1093/brain/aww097 - DOI
- 69. Reyes BA, Valentino RJ, Xu G, Van Bockstaele EJ. Hypothalamic projections to locus coeruleus neurons in rat brain. *Eur J Neurosci* 2005;22(1):93–106. doi:10.1111/j.1460-9568.2005.04197.x - DOI
- 70. Vila-Pueyo M, Strother LC, Kefel M, et al. Divergent influences of the locus coeruleus on migraine pathophysiology. *Pain* 2019;160(2):385–394. doi:10.1097/j.pain.0000000000001421 - DOI
- 71. Schwedt TJ, Zuniga L, Chong CD. Low heat pain thresholds in migraineurs between attacks. *Cephalalgia* 2015;35(7):593–599. doi:10.1177/0333102414550417 - DOI
- 72. Strupf M, Fraunberger B, Messlinger K, Namer B. Cyclic changes in sensations to painful stimuli in migraine patients. *Cephalalgia* 2019;39(5):585–596. doi:10.1177/0333102418793641 - DOI
- 73. Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. The origin of nausea in migraine—a PET study. *J Headache Pain* 2014;15(1):84. doi:10.1186/1129-2377-15-84 - DOI
- 74. Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. *Curr Pain Headache Rep* 2003;7(5):371–376. doi:10.1007/s11916-003-0036-y - DOI
- 75. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. *Brain* 2003;126(pt 8):1801–1813. doi:10.1093/brain/awg190 - DOI



- 76. Leao AAP. Further observations on the spreading depression of activity in the cerebral cortex. *J Neurophysiol* 1947;10(6):409–414. doi:10.1152/jn.1947.10.6.409 - DOI
- 77. Lauritzen M, Dreier JP, Fabricius M, et al. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 2011;31(1):17–35. doi:10.1038/jcbfm.2010.191 - DOI
- 78. Burstein R, Strassman A, Moskowitz M. Can cortical spreading depression activate central trigeminovascular neurons without peripheral input? Pitfalls of a new concept. *Cephalalgia* 2012;32(6):509–511. doi:10.1177/0333102411436262 - DOI
- 79. Goadsby PJ, Akerman S. The trigeminovascular system does not require a peripheral sensory input to be activated—migraine is a central disorder. Focus on ‘Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system’. *Cephalalgia* 2012;32(1):3–5. doi:10.1177/0333102411430267 - DOI
- 80. Hansen JM, Baca SM, Vanvalkenburgh P, Charles A. Distinctive anatomical and physiological features of migraine aura revealed by 18 years of recording. *Brain* 2013;136(pt 12):3589–3595. doi:10.1093/brain/awt309 - DOI
- 81. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. *Physiol Rev* 2017;97(2):553–622. doi:10.1152/physrev.00034.2015 - DOI
- 82. Skorobogatikh K, van Hoogstraten WS, Degan D, et al. Functional connectivity studies in migraine: what have we learned? *J Headache Pain* 2019;20(1):108. doi:10.1186/s10194-019-1047-3 - DOI
- 83. Amin FM, Hougaard A, Magon S, et al. Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. *Neurology* 2016;86(2):180–187. doi:10.1212/WNL.0000000000002261 - DOI
- 84. Xue T, Yuan K, Cheng P, et al. Alterations of regional spontaneous neuronal activity and corresponding brain circuit changes during resting state in migraine without aura. *NMR Biomed* 2013;26(9):1051–1058. doi:10.1002/nbm.2917 - DOI
- 85. Amin FM, Hougaard A, Magon S, et al. Altered thalamic connectivity during spontaneous attacks of migraine without aura: a resting-state fMRI study. *Cephalalgia* 2018;38(7):1237–1244. doi:10.1177/0333102417729113 - DOI
- 86. Moulton EA, Becerra L, Johnson A, et al. Altered hypothalamic functional connectivity with autonomic circuits and the locus coeruleus in migraine. *PloS One* 2014;9(4):e95508. doi:10.1371/journal.pone.0095508 - DOI
- 87. Schwedt TJ, Schlaggar BL, Mar S, et al. Atypical resting-state functional connectivity of affective pain regions in chronic migraine. *Headache* 2013;53(5):737–751. doi:10.1111/head.12081 - DOI
- 88. Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. *Expert Opin Ther Targets* 2020;24(2):91–100. doi:10.1080/14728222.2020.1724285 - DOI
- 89. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. *Annu Rev Pharmacol Toxicol* 2015;55:533–552. doi:10.1146/annurev-pharmtox-010814-124701 - DOI
- 90. Edvinsson L, Tajti J, Szalárdy L, Vécsei L. PACAP and its role in primary headaches. *J Headache Pain* 2018;19(1):21. doi:10.1186/s10194-018-0852-4 - DOI
- 91. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. *Pain* 2004;109(3):367–378. doi:10.1016/j.pain.2004.02.005 - DOI
- 92. Martins-Oliveira M, Akerman S, Holland PR, et al. Neuroendocrine signaling modulates specific neural networks relevant to migraine. *Neurobiol Dis* 2017;101:16–26. doi:10.1016/j.nbd.2017.01.005 - DOI

+



○



●



THANK YOU

Gage Rodriguez MD

Email: gage.rodriguez@ochsner.org

